The Food and Drug Administration has recently expanded the approval of Moderna’s RSV vaccine, known as mResvia, to include adults aged 18 to 59 who are at high risk of severe illness if they contract respiratory syncytial virus. This marks a significant milestone as the vaccine was previously only licensed for adults aged 60 and older.
Moderna CEO Stéphane Bancel expressed his satisfaction with the approval, stating that RSV poses a serious health risk to adults with certain chronic conditions. This expansion of the license will help protect additional populations from severe illness caused by RSV.
The approval comes at a crucial time for Moderna, as the company has faced challenges due to skepticism surrounding its messenger RNA vaccine platform, particularly among supporters of health secretary Robert F. Kennedy Jr. Critics have raised concerns about Moderna’s mRNA vaccines, including the recently approved mNexspike Covid-19 vaccine, which has restrictions on who can receive the shots.
Despite the challenges, Moderna’s RSV vaccine has received a positive reception, with the next step in its path to expanded use already cleared. The Advisory Committee on Immunization Practices has voted to recommend the use of the RSV vaccine in adults aged 50 to 59 with medical conditions that increase their risk from the virus. This recommendation is expected to include the Moderna vaccine following the FDA’s approval of the age extension.
However, the recommendation from ACIP is currently awaiting approval from the CDC director or the Health and Human Services Department secretary. Without this approval, health insurers may not cover the cost of the vaccine for individuals in the new age group.
In a recent development, Kennedy fired the entire ACIP in an effort to restore public confidence in vaccines, appointing new members to the committee. Despite these changes, Moderna remains committed to making mResvia available for both younger adults at increased risk and older adults for the upcoming respiratory virus season.
In conclusion, the expansion of Moderna’s RSV vaccine approval is a significant advancement in protecting high-risk populations from severe illness. As the company navigates challenges and changes in the regulatory landscape, its commitment to providing safe and effective vaccines remains steadfast.
